Global languages
2007-10-30
Regulatory

CELLAVISION AB (publ) Interim report for the period January 1 - September 30, 2007

  •    Net sales for the period increased by 40% and amounted to SEK 55.1 million (39.3). Net sales for the third quarter were SEK 21.1 million (11.6).
  •    Operating result for the period was SEK 0.1 million (-7.3), and for the third quarter SEK 3.8 million (-2.3).
  •    Net result per share amounted to SEK -0.01 million (-0.32) for the period.
  •    Liquid assets amounted to SEK 16.2 million at the end of the period.
  •    The new application for bodily fluids was previewed in the USA.
    •  
    Important events after the reporting period
  •    An evaluation of a potential future establishment on the Japanese market was initiated.
    •  


      CellaVision in summary
     
     
     
     
      (MSEK)
     
     
    Q3 2007
    Q3 2006
    Jan 1 - Sept 30 2007
     
    Jan 1 - Sept 30 2006
     
    Full year 2006
      Net sales
    21,1
    11,6
    55,1
    39,3
    54,8
      Gross profit
    11,4
    6,4
    31,2
    21,8
    32,0
      Operating result
    3,8
    -2,3
    0,1
    -7,3
    -8,6
      Net result
    3,7
    -2,4
    -0,2
    -7,6
    -8,8
      Cash flow
    7,5
    0,9
    -0,5
    0,6
      -0,8
     
     
    CEO's comment
    "CellaVision is closing in on the goal of reaching positive turnover during 2007. However, the individual quarterly periods are difficult to compare because the company still is in a phase of rapid growth, and very dependent on its distributors and their success in sales," says Yvonne Mårtensson, CEO of CellaVision.
     
    "Yet another three Nordic hospitals have decided to use CellaVison's products during the third quarter. One of them - Malmö University Hospital, our very first client - has upgraded from the DiffMaster to a CellaVision DM96. In addition to continuing to fortify our position on markets where we are already established, we are also evaluating the Japanese market. Our products are well in line with the Japanese market, which is characterised by large automated laboratories."
     
    Yvonne Mårtensson
    CEO CellaVision AB
     
     
    For more information please contact:
    Yvonne Mårtensson, CEO. Tel: +46 708 33 77 82, e-mail: yvonne.martensson@cellavision.se
    Johan Wennerholm, CFO. Tel: +46 708 33 81 68, e-mail: johan.wennerholm@cellavision.se
     
    Download the report by pressing the link below.

    Attachments

    Interim report for the period January 1 - September 30, 2007

    Share